dalbavancin (dalvance) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin. Modifications from these older glycoprotein classes allowed a similar mechanism of action with increased activity and once weekly dosing. Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, and S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus). Under the brand name DALVANCE Dalbavancin is indicated for acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms. The bactericidal action of dalbavancin results primarily from inhibition of cell-wall biosynthesis. Specifically, dalbavancin prevents incorporation of N-acetylmuramic acid (NAM)- and N-acetylglucosamine (NAG)-peptide subunits from being incorporated into the peptidoglycan matrix; which forms the major structural component of Gram-positive cell walls. The large hydrophilic molecule is able to form hydrogen bond interactions with the terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides, which is normally a five-point interaction. Binding of dalbavancin to the D-Ala-D-Ala prevents the incorporation of the NAM/NAG-peptide subunits into the peptidoglycan matrix. In addition, dalbavancin alters bacterial-cell-membrane permeability and RNA synthesis.   NCATS

Chemistry

  • SMILES: CN[C@H]1C(=O)N[C@@H]2Cc3ccc(Oc4cc5cc(Oc6ccc(cc6Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]5NC(=O)[C@@H](NC2=O)c8cc(Oc9cc1ccc9O)cc(O)c8Cl)c%10ccc(O)c(c%10)c%11c(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]%12O)cc(O)cc%11[C@H](NC7=O)C(=O)NCCCN(C)C)c4O[C@@H]%13O[C@@H]([C@@H](O)[C@H](O)[C@H]%13NC(=O)CCCCCCCCC(C)C)C(=O)O)cc3
  • InChIKey: KGPGQDLTDHGEGT-SZUNQUCBSA-N
  • Mol. Mass: 1816.72
  • ALogP: Missing data
  • ChEMBL Molecules:
    dalbavancin  
    dalbavancin hydrochloride  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$1149.1100 - $1532.2700
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

5,31-dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-o­ [2-deoxy-2-[(10-methylundecanoyl)amino]-β-d-glucopyranuronosyl]-38-[[3-(dimethylamino)propyl] carbamoyl]-42-o-α-d-mannopyranosyl-15-n-methyl(ristomycin a aglycone) hydrochloride | a-a-1 | bi397 | bi-397 | dalbavancin | dalbavancin b0 | dalbavancin hcl | dalbavancin hydrochloride | dalvance | mdl 63,397 | mdl-64397 | ver001 | vero001 | xydalba

Organizations (24)

Research & Development (23)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (24)

Approved Indications (1)


 

Skin Diseases, Bacterial (approved 2014)

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Abscess (Phase 3)

Arthritis, Infectious (Phase 4)

Bacteremia (Phase 2)

Bacterial Infections (Phase 4)

Bone Diseases, Infectious (Phase 4)

Catheter-Related Infections (Phase 3)

Cellulitis (Phase 3)

Community-Acquired Infections (Phase 3)

Endocarditis (Phase 2)

Gram-Positive Bacteria (Phase 2/Phase 3)

Gram-Positive Bacterial Infections (Phase 4)

Infections (Phase 4)

Methicillin-Resistant Staphylococcus aureus (Phase 3)

Osteomyelitis (Phase 4)

Peritonitis (Phase 4)

Prosthesis-Related Infections (Phase 4)

Soft Tissue Infections (Phase 4)

Staphylococcal Infections (Phase 3)

Staphylococcal Skin Infections (Phase 3)

Substance Abuse, Intravenous (Phase 2/Phase 3)

Substance-Related Disorders (Phase 2/Phase 3)

Surgical Wound Infection (Phase 3)

Wound Infection (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 23
  • # of Trial Organizations: 23

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue